Arxis (NASDAQ: ARXS) delivered its second public quarter exactly the way a freshly public Arcline compounder is supposed to: revenue of $501 million grew 25%, including 21% organic, with both segments and all three end markets contributing. Adjusted EBITDA of $211 million grew 38% and the margin expanded 390 basis points to 42.2%, well above the 38.4% reported a year ago. Free cash flow nearly quadrupled. Management raised full-year guidance for revenue, Adjusted EBITDA, and margin in a single earnings release - and the company announced or closed two more acquisitions inside the same quarter. On the GAAP line (Generally Accepted Accounting Principles), the quarter was a loss of $(5) million and diluted loss per share of $(0.01), because a $107 million share-based compensation charge tied to the April initial public offering is amortizing through the P&L. Adjusted diluted earnings per share of $0.28 was up 726% year over year on the cleaner basis. The thesis investors are paying for is unchanged: an aerospace-and-defense parts roll-up compounding organically in the high teens to low twenties while a disciplined acquisition machine drops more businesses into the same two-segment chassis every quarter. The market has already endorsed the thesis - Arxis opened its first trading day at $38.00 against a $28.00 IPO price, fell to a 52-week low of $33.15 on May 19, then climbed to a 52-week high of $61.50 on August 6, and closed the report date at $57.69, up roughly 74% from offer in four months and around 6% from the post-IPO high. At $57.69 and a $24 billion equity capitalization, the stock trades at roughly 32x the midpoint of freshly raised FY2026 Adjusted EBITDA, an aggressive multiple for an industrial compounder that already needs to keep raising guidance to justify the bid. The quarter proved the business; the question the report answers is what the market is paying for, what would have to go wrong to break the multiple, and what the company has to deliver next.